Why the Painchek (ASX:PCK) share price lifted today

The Painchek (ASX: PCK) share price was up more than 4% at close of trade after the company released its quarterly report today.

| More on:
medical asx share price represented by doctor giving thumbs up

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Painchek Ltd (ASX: PCK) share price climbed today after the company provided the market with a positive quarterly update for December 2020.

Shares in the small cap healthcare company were trading 4.2% higher at 7.4 cents on close of trade today.

What is driving the Painchek share price

In today's release, the company reported continued growth in its aged care and initial entry into the hospital, home care and disability markets during the quarter ended 31 December.

In its core aged care market segment, Painchek delivered sales growth of 7% from the prior quarter. And with its global licences covering 71,318 beds, year on year (YoY) growth is up 123%. The company reported its domestic sales now reflect more than 30% of Australia's domestic aged care market share.

As a result, Painchek now has 884 aged care clients, up 133% YoY, and the forward looking revenue equates to more than $3 million annualised recurring revenue.

However it was not all smooth sailing for the company, with several large provider agreements delayed as a result of COVID-19 disruptions. Paincheck said these discussions have since been resumed in January.

Management comments

Painchek CEO Philip Daffas welcomed the update, saying:

While 2020 was challenging for many businesses, we successfully continued to deliver with significant sales growth. This included pivoting to a fully digital sales and delivery model that met the immediate needs of our clients, as well as establishing a new cost-effective global go-to-market model.

About the company

PainChek develops and commercialises medical device applications. This is aimed specifically at automating intelligent pain assessment of individuals who are unable to communicate their pain with carers (such as people in aged care facilities).

In particular, the company is involved in the provision of pain management and better medication for residents living with dementia and other communication difficulties. Painchek has already obtained regulatory clearance in Australia and Europe.

Should you invest $1,000 in Platinum Capital Limited right now?

Before you buy Platinum Capital Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Platinum Capital Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Guess how much $10,000 invested in Zip shares on 7 April is worth today!

The rebound in the Zip share price since 7 April has been nothing short of remarkable.

Read more »

Smiling man working on his laptop.
Share Market News

17 ASX 200 stocks to benefit from the US-China tariff pause: broker

Macquarie reveals the ASX 200 shares that are likely to feel a tailwind from the 90-day tariff deal.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Are Super Retail Group shares a buy, hold, or sell according to Macquarie?

Let's see what the broker is saying about this popular retail stock.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Broker Notes

What does Macquarie think Steadfast shares are worth?

Could big returns be on offer from this blue chip? Let's find out.

Read more »

Man smiling at a laptop because of a rising share price.
Share Market News

How are ASX 200 investors reacting to the surprise US-China tariff deal?

The Nasdaq rocketed 4.4% on the US-China tariff agreement, but what about the ASX 200?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Opinions

Here's what I'd do after the big ASX stock market rally

The US and China are working towards a trade deal.

Read more »

Two hands being shaken symbolising a deal.
Opinions

2 ASX 200 shares I'd buy after the US-China tariff deal

These stocks look appealing to me right now.

Read more »

Hand with AI in capital letters and AI-related digital icons.
Share Market News

ASX stocks Macquarie says are impacted by artificial intelligence

Here’s what Macquarie thinks about these companies. 

Read more »